Cellectar Biosciences, a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, has entered into a commercial manufacturing and supply agreement with Evergreen Theragnostics, a global radiopharmaceutical contract development and manufacturing organization (CDMO) based in Springfield, NJ. The company also announced that the United States Adopted Names Council (USAN) has approved the use of “iopofosine I-131” as the generic name...